Emtricitabine
Code | Size | Price |
---|
TAR-T6214-50mg | 50mg | £107.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6214-100mg | 100mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6214-500mg | 500mg | £161.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Emtricitabine (FTC), a nucleoside reverse transcriptase inhibitor, exhibits inhibition activity against human immunodeficiency virus (HIV) and hepatitis B virus.
CAS:
143491-57-0
Formula:
C8H10FN3O3S
Molecular Weight:
247.24
Pathway:
Proteases/Proteasome; Microbiology/Virology
Purity:
0.9993
SMILES:
Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1
Target:
HIV Protease; Reverse Transcriptase
References
Venhoff N, et al. Antivir Ther, 2007, 12(7), 1075-1085.
Borroto-Esoda K, et al. Antivir Ther, 2006, 11(3), 377-384.
Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692.
Bao H, Yan J, Huang J, et al.Activation of endogenous retrovirus triggers microglial immuno-inflammation and contributes to negative emotional behaviors in mice with chronic stress.Journal of Neuroinflammation.2023, 20(1): 1-16.
Richman DD, et al. Antivir Ther, 2001, 6(2), 83-88.
Faltz M, et al. Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP. Cardiovasc Toxicol. 2017 Jan 3. [Epub ahead of print]
Hazen R, et al. J Acquir Immune Defic Syndr, 2003, 32(3), 255-258.
Saag MS, et al. Clin Infect Dis, 2006, 42(1), 126-131.